Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]
Ted Raad
Recent Posts
Colombia Oil and Gas 2023 Congress – Status and Developments Prospects of Oil and Gas industry in Latin America
Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023
Künstliche Intelligenz im Kinderherz-Zentrum
Auri Inc. – Dividend, Retirement Timelines and Expectations
Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update
Sign Up To Get Our Instant Alerts!

Popular Post
-
Toyota Suspends Production at 2 Plants in Japan Citing Chip Shortage 53 views
-
Japanese Premier Declares COVID-19 State of Emergency in Tokyo 50 views
-
Expect Even More Unique Electric Cars Says Ferrari 44 views
-
Kimberly Goldwin Poised to Become Next President of ABC News 30 views
-
Records Show 19,000 U.S Based Amazon Employees Contracted Coronavirus 28 views